FindTrial
Sign In

EV

BIOLOGICAL5 trials

Sponsors

University of Jordan, Merck Sharp & Dohme LLC, Eli Lilly and Company

Conditions

Bladder CancerCarcinoma, Transitional CellMetastatic Urothelial CarcinomaNeoplasm MetastasisPremature Ovarian FailureUrinary Bladder NeoplasmsUrothelial NeoplasmsVitiligo

Phase 1

The Use of Expandeded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult Humans
Active, not recruitingNCT04815213
University of JordanPremature Ovarian Failure
Start: 2022-01-01End: 2027-01-31Updated: 2025-01-28
A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)
Active, not recruitingNCT05845814
Merck Sharp & Dohme LLCMetastatic Urothelial Carcinoma, Urothelial Neoplasms
Start: 2023-06-23End: 2027-05-31Target: 390Updated: 2025-09-10
Use of Allogeneic Extracellular Secretomes (EV)Derived From Umbilical Cord Mesenchymal Stromal Cells: a Phase I Open-label Safety Trial.
Active, not recruitingNCT06813027
University of JordanVitiligo
Start: 2023-01-01End: 2027-01-30Updated: 2025-04-30
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
RecruitingNCT07232602
Merck Sharp & Dohme LLCBladder Cancer
Start: 2026-02-09End: 2030-10-18Target: 55Updated: 2026-04-02

Phase 3

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
RecruitingNCT07218380
Eli Lilly and CompanyCarcinoma, Transitional Cell, Neoplasm Metastasis, Urinary Bladder Neoplasms
Start: 2025-12-12End: 2033-05-01Target: 450Updated: 2026-03-19